Compass Therapeutics (NASDAQ:CMPX) Earns "Sell (D-)" Rating from Weiss Ratings

Key Points

• Compass Therapeutics has been given a "sell (D-)" rating by Weiss Ratings, while other analysts have issued varied ratings including several buy recommendations and price targets as high as $32.00.
• The company's stock recently traded at $3.97 with a market cap of approximately $548.97 million, reflecting a significant 52 week range of $1.27 to $4.86.
• Compass Therapeutics reported a earnings per share of ($0.14), missing expectations and is projected to post an EPS of -0.36 for the current fiscal year.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report)'s stock had its "sell (d-)" rating reissued by research analysts at Weiss Ratings in a report issued on Friday,Weiss Ratings reports.

A number of other equities research analysts have also weighed in on the company. Guggenheim lifted their price objective on Compass Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Tuesday, August 12th. Lifesci Capital began coverage on Compass Therapeutics in a research note on Monday, October 6th. They issued an "outperform" rating and a $10.00 price target for the company. D. Boral Capital reiterated a "buy" rating and issued a $32.00 price target on shares of Compass Therapeutics in a report on Tuesday, August 12th. Compass Point set a $10.00 price objective on shares of Compass Therapeutics in a report on Monday, October 6th. Finally, Raymond James Financial raised shares of Compass Therapeutics to an "outperform" rating and set a $9.00 target price for the company in a research report on Tuesday, July 1st. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Compass Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $13.10.

Compass Therapeutics Price Performance

Compass Therapeutics stock traded up $0.08 during trading hours on Friday, reaching $3.97. The stock had a trading volume of 843,015 shares, compared to its average volume of 1,950,434. The company has a fifty day simple moving average of $3.61 and a 200-day simple moving average of $2.81. Compass Therapeutics has a 52 week low of $1.27 and a 52 week high of $4.86. The stock has a market cap of $548.97 million, a PE ratio of -8.82 and a beta of 1.48.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). Research analysts predict that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Institutional Trading of Compass Therapeutics

A number of hedge funds have recently modified their holdings of CMPX. Creative Planning purchased a new stake in shares of Compass Therapeutics in the 2nd quarter worth about $30,000. Strs Ohio bought a new stake in Compass Therapeutics during the first quarter worth about $34,000. Apollon Wealth Management LLC bought a new stake in Compass Therapeutics during the third quarter worth about $35,000. Birchview Capital LP purchased a new stake in Compass Therapeutics in the first quarter worth about $46,000. Finally, Walleye Trading LLC bought a new position in shares of Compass Therapeutics during the first quarter valued at approximately $48,000. Institutional investors own 68.43% of the company's stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.